Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.
A 12-week double-blind placebo-controlled trial to study the effects of metformin on lipoprotein concentration and composition was performed in forty patients with NIDDM and hyperlipoproteinemia. A significant decrease occurred in VLDL-apo B and all lipid components of VLDL, indicating a decreased number of circulating VLDL, while LDL-apo B was unchanged. Moreover in VLDL the relative TG content increased, the cholesterol content decreased, while in LDL the TG content decreased and the cholesterol content increased, indicating a change in the particle distribution over the spectrum VLDL-IDL-LDL. The initially enhanced TG-content in HDL was reduced. While a reduction in VLDL is observed with all methods improving glucose control the observed compositional changes in VLDL and LDL have not been described before and may be a specific effect of metformin.
Schneider
J
J
Department of Internal Medicine, Philipps-University Marburg, Germany.
D000368:Aged; D001059:Apoproteins / Q000097:blood* / Q000187:drug effects; D001161:Arteriosclerosis / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood* / Q000209:etiology; D008055:Lipids / Q000097:blood*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D012307:Risk Factors
D001059:Apoproteins; D008055:Lipids; D008687:Metformin